A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)

The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma. The study will be conducted in a population of male and female subjects aged 18 years and older, with confirmed symptomatic multiple myeloma with measurable disease, who have received one prior line of therapy that included a proteasome inhibitor and lenalidomide and were refractory to lenalidomide, or who have received two or three prior lines of therapy that

Trial Details

NCT ID
NCT07742215
Phase
PHASE3
Sponsor
Biocad
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • BCD-248 + daratumumab
  • Daratumumab + pomalidomide + dexamethasone
Locations (sample)
  • Homyel, Belarus|52.4345,30.9754
  • Chelyabinsk, Russia|55.1611,61.42877
  • Irkutsk, Russia|52.29566,104.29076
  • Kazan', Russia|55.78874,49.12214
  • Krasnoyarsk, Russia|56.03742,92.93136

Key Eligibility Criteria

  • Signed informed consent form.
  • Age ≥18 years.
  • Documented diagnosis of multiple myeloma according to the IMWG criteria.
  • Measurable disease at screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →